Continuum Advisory’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$837K Buy
6,008
+297
+5% +$41.6K 0.08% 214
2025
Q4
$701K Buy
5,711
+573
+11% +$69.6K 0.07% 236
2025
Q3
$570K Buy
5,138
+209
+4% +$23.8K 0.06% 258
2025
Q2
$546K Buy
4,929
+355
+8% +$37.8K 0.07% 251
2025
Q1
$513K Sell
4,574
-47
-1% -$4.85K 0.07% 231
2024
Q4
$427K Sell
4,621
-13
-0.3% -$1.17K 0.05% 265
2024
Q3
$427K Sell
4,634
-21
-0.5% -$1.6K 0.05% 268
2024
Q2
$319K Sell
4,655
-442
-9% -$29.5K 0.05% 294
2024
Q1
$329K Sell
5,097
-8,894
-64% -$684K 0.05% 289
2023
Q4
$1.13M Buy
13,991
+539
+4% +$41.9K 0.16% 156
2023
Q3
$1.01M Sell
13,452
-125
-0.9% -$9.62K 0.16% 162
2023
Q2
$1.05M Sell
13,577
-5,740
-30% -$458K 0.17% 157
2023
Q1
$1.6M Sell
19,317
-781
-4% -$64.7K 0.27% 105
2022
Q4
$1.73M Buy
20,098
+764
+4% +$60.5K 0.31% 92
2022
Q3
$1.19M Buy
19,334
+666
+4% +$42K 0.21% 129
2022
Q2
$1.15M Buy
18,668
+4,187
+29% +$259K 0.21% 131
2022
Q1
$859K Buy
+14,481
New +$926K 0.16% 155
2021
Q3
Sell
-4,135
Closed -$285K 299
2021
Q2
$285K Sell
4,135
-169
-4% -$11.3K 0.09% 217
2021
Q1
$283K Sell
4,304
-739
-15% -$47.7K 0.12% 141
2020
Q4
$294K Hold
5,043
0.13% 121
2020
Q3
$319K Sell
5,043
-1,474
-23% -$102K 0.17% 113
2020
Q2
$496K Buy
6,517
+1,597
+32% +$122K 0.31% 73
2020
Q1
$357K Buy
+4,920
New +$340K 0.24% 90

Other funds holding GILD

Continuum Advisory's GILD Position: Q1 2026 in Review

Continuum Advisory increased its Gilead Sciences (GILD) stake by 5.2% in Q1 2026, buying an estimated $41.6K and bringing the position to 6,008 shares worth $837K. The position accounts for 0.08% of the portfolio, ranked #214.

Continuum Advisory first reported a position in GILD in Q1 2020 and has held it in 23 quarters since. The position peaked at $1.73M in Q4 2022. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Continuum Advisory held 6,008 shares of Gilead Sciences worth $837K as of Q1 2026.
  • Continuum Advisory bought 297 Gilead Sciences shares in Q1 2026, an estimated $41.6K.
  • Gilead Sciences made up 0.08% of Continuum Advisory's portfolio in Q1 2026, its #214 holding.
  • Continuum Advisory first reported a position in Gilead Sciences in Q1 2020 and has held it in 23 quarters since.
  • Continuum Advisory's Gilead Sciences position peaked at $1.73M in Q4 2022.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Continuum Advisory's 13F filing for Q1 2026, filed 22 Apr 2026.